ESR1 and neoplasm: Subsequent studies demonstrated that in hormone-refractory prostate cancer, the reactivation of the ESR1 steroidal pathway could support tumor progression and invasiveness by enhancing the interaction between cancer cells and nerve cells, promoting both local invasion and metastasis [33,35,36].